TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// TI - Cancer statistics, 2018 JO - CA Cancer J Clin. VL - 68 UR - https://doi.org/10.3322/caac.21442 DO - 10.3322/caac.21442 ID - Siegel2018 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Fedewa, S. A. AU - Ahnen, D. J. AU - Meester, R. G. S. AU - Barzi, A. PY - 2017 DA - 2017// TI - Colorectal cancer statistics, 2017 JO - CA Cancer J Clin. VL - 67 UR - https://doi.org/10.3322/caac.21395 DO - 10.3322/caac.21395 ID - Siegel2017 ER - TY - JOUR AU - Shah, M. A. AU - Renfro, L. A. AU - Allegra, C. J. AU - Andre, T. AU - Gramont, A. AU - Schmoll, H. J. PY - 2016 DA - 2016// TI - Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database JO - J Clin Oncol. VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.0558 DO - 10.1200/JCO.2015.63.0558 ID - Shah2016 ER - TY - JOUR AU - Guinney, J. AU - Dienstmann, R. AU - Wang, X. AU - Reynies, A. AU - Schlicker, A. AU - Soneson, C. PY - 2015 DA - 2015// TI - The consensus molecular subtypes of colorectal cancer JO - Nat Med. VL - 21 UR - https://doi.org/10.1038/nm.3967 DO - 10.1038/nm.3967 ID - Guinney2015 ER - TY - JOUR AU - Fontana, E. AU - Eason, K. AU - Cervantes, A. AU - Salazar, R. AU - Sadanandam, A. PY - 2019 DA - 2019// TI - Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials JO - Ann Oncol. VL - 30 UR - https://doi.org/10.1093/annonc/mdz052 DO - 10.1093/annonc/mdz052 ID - Fontana2019 ER - TY - JOUR AU - Wu, C. PY - 2018 DA - 2018// TI - Systemic therapy for colon cancer JO - Surg Oncol Clin N Am. VL - 27 UR - https://doi.org/10.1016/j.soc.2017.11.001 DO - 10.1016/j.soc.2017.11.001 ID - Wu2018 ER - TY - JOUR AU - Douillard, J. Y. AU - Oliner, K. S. AU - Siena, S. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. PY - 2013 DA - 2013// TI - Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer JO - N Engl J Med. VL - 369 UR - https://doi.org/10.1056/NEJMoa1305275 DO - 10.1056/NEJMoa1305275 ID - Douillard2013 ER - TY - JOUR AU - Bokemeyer, C. AU - Kohne, C. H. AU - Ciardiello, F. AU - Lenz, H. J. AU - Heinemann, V. AU - Klinkhardt, U. PY - 2015 DA - 2015// TI - FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer JO - Eur J Cancer. VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.04.007 DO - 10.1016/j.ejca.2015.04.007 ID - Bokemeyer2015 ER - TY - JOUR AU - Cutsem, E. AU - Lenz, H. J. AU - Kohne, C. H. AU - Heinemann, V. AU - Tejpar, S. AU - Melezinek, I. PY - 2015 DA - 2015// TI - Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer JO - J Clin Oncol. VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.4812 DO - 10.1200/JCO.2014.59.4812 ID - Cutsem2015 ER - TY - JOUR AU - Peeters, M. AU - Kafatos, G. AU - Taylor, A. AU - Gastanaga, V. M. AU - Oliner, K. S. AU - Hechmati, G. PY - 2015 DA - 2015// TI - Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials JO - Eur J Cancer. VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.05.017 DO - 10.1016/j.ejca.2015.05.017 ID - Peeters2015 ER - TY - JOUR AU - Roth, A. D. AU - Tejpar, S. AU - Delorenzi, M. AU - Yan, P. AU - Fiocca, R. AU - Klingbiel, D. PY - 2010 DA - 2010// TI - Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial JO - J Clin Oncol. VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.3452 DO - 10.1200/JCO.2009.23.3452 ID - Roth2010 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med. VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Tabernero, J. AU - Cutsem, E. AU - Lakomy, R. AU - Prausova, J. AU - Ruff, P. AU - Hazel, G. A. PY - 2014 DA - 2014// TI - Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial JO - Eur J Cancer. VL - 50 UR - https://doi.org/10.1016/j.ejca.2013.09.013 DO - 10.1016/j.ejca.2013.09.013 ID - Tabernero2014 ER - TY - JOUR AU - Arnold, D. AU - Lueza, B. AU - Douillard, J. Y. AU - Peeters, M. AU - Lenz, H. J. AU - Venook, A. PY - 2017 DA - 2017// TI - Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials JO - Ann Oncol. VL - 28 UR - https://doi.org/10.1093/annonc/mdx175 DO - 10.1093/annonc/mdx175 ID - Arnold2017 ER - TY - JOUR AU - Grothey, A. AU - Cutsem, E. AU - Sobrero, A. AU - Siena, S. AU - Falcone, A. AU - Ychou, M. PY - 2013 DA - 2013// TI - Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial JO - Lancet. VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61900-X DO - 10.1016/S0140-6736(12)61900-X ID - Grothey2013 ER - TY - JOUR AU - Cutsem, E. AU - Martinelli, E. AU - Cascinu, S. AU - Sobrero, A. AU - Banzi, M. AU - Seitz, J. F. PY - 2019 DA - 2019// TI - Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study JO - Oncologist. VL - 24 UR - https://doi.org/10.1634/theoncologist.2018-0072 DO - 10.1634/theoncologist.2018-0072 ID - Cutsem2019 ER - TY - JOUR AU - Li, J. AU - Qin, S. AU - Xu, R. AU - Yau, T. C. AU - Ma, B. AU - Pan, H. PY - 2015 DA - 2015// TI - Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70156-7 DO - 10.1016/S1470-2045(15)70156-7 ID - Li2015 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 Blockade in tumors with mismatch-repair deficiency JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Overman, M. J. AU - McDermott, R. AU - Leach, J. L. AU - Lonardi, S. AU - Lenz, H. J. AU - Morse, M. A. PY - 2017 DA - 2017// TI - Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30422-9 DO - 10.1016/S1470-2045(17)30422-9 ID - Overman2017 ER - TY - STD TI - Noone AM HN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. 2018 [Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 7 SEER data submission, posted to the SEER web site, April 8.]. UR - https://seer.cancer.gov/csr/1975_2015/ ID - ref20 ER - TY - JOUR AU - Loree, J. M. AU - Pereira, A. A. L. AU - Lam, M. AU - Willauer, A. N. AU - Raghav, K. AU - Dasari, A. PY - 2018 DA - 2018// TI - Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes JO - Clin Cancer Res. VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-2484 DO - 10.1158/1078-0432.CCR-17-2484 ID - Loree2018 ER - TY - JOUR AU - Cremolini, C. AU - Schirripa, M. AU - Antoniotti, C. AU - Moretto, R. AU - Salvatore, L. AU - Masi, G. PY - 2015 DA - 2015// TI - First-line chemotherapy for mCRC-a review and evidence-based algorithm JO - Nat Rev Clin Oncol. VL - 12 UR - https://doi.org/10.1038/nrclinonc.2015.129 DO - 10.1038/nrclinonc.2015.129 ID - Cremolini2015 ER - TY - JOUR AU - Wesselmann, S. AU - Winter, A. AU - Ferencz, J. AU - Seufferlein, T. AU - Post, S. PY - 2014 DA - 2014// TI - Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013 JO - Int J Colorectal Dis. VL - 29 UR - https://doi.org/10.1007/s00384-014-1842-x DO - 10.1007/s00384-014-1842-x ID - Wesselmann2014 ER - TY - JOUR AU - Morris, E. AU - Haward, R. A. AU - Gilthorpe, M. S. AU - Craigs, C. AU - Forman, D. PY - 2006 DA - 2006// TI - The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire's colorectal cancer patients JO - Br J Cancer. VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603372 DO - 10.1038/sj.bjc.6603372 ID - Morris2006 ER - TY - JOUR AU - Kilsdonk, M. J. AU - Dijk, B. A. AU - Otter, R. AU - Siesling, S. AU - Harten, W. H. PY - 2014 DA - 2014// TI - The impact of organisational external peer review on colorectal cancer treatment and survival in the Netherlands JO - Br J Cancer. VL - 110 UR - https://doi.org/10.1038/bjc.2013.814 DO - 10.1038/bjc.2013.814 ID - Kilsdonk2014 ER - TY - JOUR AU - MacDermid, E. AU - Hooton, G. AU - MacDonald, M. AU - McKay, G. AU - Grose, D. AU - Mohammed, N. PY - 2009 DA - 2009// TI - Improving patient survival with the colorectal cancer multi-disciplinary team JO - Colorectal Dis. VL - 11 UR - https://doi.org/10.1111/j.1463-1318.2008.01580.x DO - 10.1111/j.1463-1318.2008.01580.x ID - MacDermid2009 ER - TY - JOUR AU - Lordan, J. T. AU - Karanjia, N. D. AU - Quiney, N. AU - Fawcett, W. J. AU - Worthington, T. R. PY - 2009 DA - 2009// TI - A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting JO - Eur J Surg Oncol. VL - 35 UR - https://doi.org/10.1016/j.ejso.2008.01.028 DO - 10.1016/j.ejso.2008.01.028 ID - Lordan2009 ER - TY - JOUR AU - Cutsem, E. AU - Cervantes, A. AU - Adam, R. AU - Sobrero, A. AU - Krieken, J. H. AU - Aderka, D. PY - 2016 DA - 2016// TI - ESMO consensus guidelines for the management of patients with metastatic colorectal cancer JO - Ann Oncol. VL - 27 UR - https://doi.org/10.1093/annonc/mdw235 DO - 10.1093/annonc/mdw235 ID - Cutsem2016 ER - TY - JOUR AU - Boeckx, N. AU - Koukakis, R. PY - 2017 DA - 2017// TI - Op de Beeck K, Rolfo C, Van Camp G, Siena S, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies JO - Ann Oncol. VL - 28 UR - https://doi.org/10.1093/annonc/mdx119 DO - 10.1093/annonc/mdx119 ID - Boeckx2017 ER - TY - JOUR AU - Holch, J. W. AU - Ricard, I. AU - Stintzing, S. AU - Modest, D. P. AU - Heinemann, V. PY - 2017 DA - 2017// TI - The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials JO - Eur J Cancer. VL - 70 UR - https://doi.org/10.1016/j.ejca.2016.10.007 DO - 10.1016/j.ejca.2016.10.007 ID - Holch2017 ER - TY - JOUR AU - Cummings, L. C. AU - Payes, J. D. AU - Cooper, G. S. PY - 2007 DA - 2007// TI - Survival after hepatic resection in metastatic colorectal cancer: a population-based study JO - Cancer. VL - 109 UR - https://doi.org/10.1002/cncr.22448 DO - 10.1002/cncr.22448 ID - Cummings2007 ER - TY - JOUR AU - Ito, H. AU - Gonen, M. AU - Fong, Y. AU - Allen, P. J. AU - DeMatteo, R. P. PY - 2010 DA - 2010// TI - Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution JO - J Am Coll Surg. VL - 210 UR - https://doi.org/10.1016/j.jamcollsurg.2009.12.040 DO - 10.1016/j.jamcollsurg.2009.12.040 ID - Ito2010 ER - TY - JOUR AU - Ruers, T. AU - Coevorden, F. AU - Punt, C. J. AU - Pierie, J. E. AU - Borel-Rinkes, I. AU - Ledermann, J. A. PY - 2017 DA - 2017// TI - Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial JO - J Natl Cancer Inst VL - 109 UR - https://doi.org/10.1093/jnci/djx015 DO - 10.1093/jnci/djx015 ID - Ruers2017 ER - TY - JOUR AU - Mody, K. AU - Baldeo, C. AU - Bekaii-Saab, T. PY - 2018 DA - 2018// TI - Antiangiogenic therapy in colorectal cancer JO - Cancer J. VL - 24 UR - https://doi.org/10.1097/PPO.0000000000000328 DO - 10.1097/PPO.0000000000000328 ID - Mody2018 ER - TY - JOUR AU - Uetake, H. AU - Yasuno, M. AU - Ishiguro, M. AU - Kameoka, S. AU - Shimada, Y. AU - Takahashi, K. PY - 2015 DA - 2015// TI - A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808) JO - Ann Surg Oncol. VL - 22 UR - https://doi.org/10.1245/s10434-014-4094-7 DO - 10.1245/s10434-014-4094-7 ID - Uetake2015 ER - TY - JOUR AU - Yasuno, M. AU - Uetake, H. AU - Ishiguro, M. AU - Mizunuma, N. AU - Komori, T. AU - Miyata, G. PY - 2019 DA - 2019// TI - mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival JO - Int J Clin Oncol. VL - 24 UR - https://doi.org/10.1007/s10147-018-01393-8 DO - 10.1007/s10147-018-01393-8 ID - Yasuno2019 ER - TY - JOUR AU - Modest, D. P. AU - Pant, S. AU - Sartore-Bianchi, A. PY - 2019 DA - 2019// TI - Treatment sequencing in metastatic colorectal cancer JO - Eur J Cancer. VL - 109 UR - https://doi.org/10.1016/j.ejca.2018.12.019 DO - 10.1016/j.ejca.2018.12.019 ID - Modest2019 ER - TY - JOUR AU - Gordon, B. E. AU - Chen, R. C. PY - 2017 DA - 2017// TI - Patient-reported outcomes in cancer survivorship JO - Acta Oncol. VL - 56 UR - https://doi.org/10.1080/0284186X.2016.1268265 DO - 10.1080/0284186X.2016.1268265 ID - Gordon2017 ER - TY - JOUR AU - Luther, C. AU - Swami, U. AU - Zhang, J. AU - Milhem, M. AU - Zakharia, Y. PY - 2019 DA - 2019// TI - Advanced stage melanoma therapies: detailing the present and exploring the future JO - Crit Rev Oncol Hematol. VL - 133 UR - https://doi.org/10.1016/j.critrevonc.2018.11.002 DO - 10.1016/j.critrevonc.2018.11.002 ID - Luther2019 ER - TY - JOUR AU - Herbst, R. S. AU - Morgensztern, D. AU - Boshoff, C. PY - 2018 DA - 2018// TI - The biology and management of non-small cell lung cancer JO - Nature. VL - 553 UR - https://doi.org/10.1038/nature25183 DO - 10.1038/nature25183 ID - Herbst2018 ER -